Therefore, maybe there are functional connections between BRCA1, PPARγ and PFKP in glycolysis system and PFKP inhibitor may have a potential effect on BRCA1 dysfunctional breast cancer patients who suffer from diabetes and need treatments with PPARγ agonists. Here, PFKP is linked to breast cancer.